TARS — Tarsus Pharmaceuticals, Inc. stock price, charts and financials
QT62Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
66.81
+2.02+3.12%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.14 | Insider Own | 5.34% | Shs Outstand | 43.02M | Perf Week | 9.74% |
| Market Cap | 2.79B | Forward P/E | 22.52 | EPS next Y | 2.88 | Insider Trans | -6.75% | Shs Float | 40.39M | Perf Month | 1.01% |
| Enterprise Value | 2.58B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 14.32% | Perf Quarter | 1.30% |
| Income | -45.99M | P/S | 4.60 | EPS this Y | -32.71% | Inst Trans | - | Short Ratio | 6.36 | Perf Half Y | 4.52% |
| Sales | 606.34M | P/B | 8.11 | EPS next Y | 290.18% | ROA | -7.60% | Short Interest | 5.78M | Perf YTD | -20.87% |
| Book/sh | - | P/C | 35.27 | EPS next 5Y | - | ROE | -13.53% | 52W High | 87.91 -24.00% | Perf Year | 55.60% |
| Cash/sh | - | P/FCF | 45.29 | EPS past 3/5Y | - | ROIC | -11.15% | 52W Low | 46.07 45.01% | Perf 3Y | 275.38% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 158.86% - | Gross Margin | 90.59% | Volatility | 6.79% 5.43% | Perf 5Y | 187.06% |
| Dividend TTM | - | EV/Sales | 4.26 | EPS Y/Y TTM | 62.87% | Oper. Margin | -8.00% | ATR (14) | 3.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.17 | Sales Y/Y TTM | 192.90% | Profit Margin | -7.67% | RSI (14) | 59.87 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.20 | EPS Q/Q | 75.00% | SMA20 | 9.00% | Beta | 0.52 | Target Price | 93.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 107.69% | SMA50 | 5.86% | Rel Volume | 1.01 | Prev Close | 64.79 |
| Employees | 370 | LT Debt/Eq | 0.27 | Earnings | Nov 10 | SMA200 | -5.30% | Avg Volume | 976.04K | Price | 66.81 |
| IPO Date | Oct 16, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 60.03% 8.33% | Net Debt/EBITDA | 5.81 | Volume | 983,150 | Change | 3.12% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | Mizuho | Outperform | $100 → $98 |
| Jul-21-26 | Reiterated | Guggenheim | Buy | $84 → $89 |
| Feb-05-26 | Reiterated | Goldman Sachs | Neutral | $51 → $68 |
| Dec-08-25 | Initiated | Barclays | Overweight | $62 → $100 |
| Nov-20-25 | Initiated | Mizuho | Outperform | $100 |
| Nov-06-25 | Reiterated | Goldman Sachs | Neutral | $45 → $51 |
| Oct-20-25 | Reiterated | HC Wainwright & Co. | Buy | $61 → $88 |
| May-02-25 | Reiterated | Guggenheim | Buy | $84 |
| Mar-06-25 | Reiterated | Jefferies | Buy | $58 |
| Jan-27-25 | Reiterated | Barclays | Overweight | $62 |
Latest News
Aug-07-26
Aug-06-26
Aug-06-2605:41PM
02:54PM
07:03AM
07:02AM
07:01AM
Aug-05-26
Aug-05-2608:02PM
Jul-31-26
Jul-31-2601:40PM
Jul-29-26
Jul-29-2611:02AM
Jul-27-26
Jul-27-2603:52AM
Jul-24-26
Jul-24-2611:57AM
Jul-21-26
Jul-21-2609:56AM
Jul-13-26
Jul-13-2604:05PM
Jul-11-26
Jul-11-2610:02AM
Company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 607 | 451 | 183 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 57 | 31 | 13 | — | — | — | — | — | — | |
| Gross Profit | 550 | 421 | 170 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 527 | 427 | 237 | — | — | — | — | — | — | |
| Research and Development | 87 | 64 | 53 | — | — | — | — | — | — | |
| Other Operating Expense | -15 | 1 | 1 | — | — | — | — | — | — | |
| Operating Income | -49 | -71 | -121 | — | — | — | — | — | — | |
| Interest Expense | 8 | 9 | 7 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 16 | 12 | — | — | — | — | — | — | |
| Net Income Before Taxes | -44 | -64 | -116 | — | — | — | — | — | — | |
| Income Taxes | 3 | 2 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -47 | -66 | -116 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -47 | -66 | -116 | — | — | — | — | — | — | |
| Net Income | -47 | -66 | -116 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.09 | -1.59 | -3.07 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.09 | -1.59 | -3.07 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.09 | -1.59 | -3.07 | — | — | — | — | — | — | |
| EBITDA | -36 | -54 | -106 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.73 | 7.63 | 11.50 | — | — | — | — | — | — | |
| Gross Margin | 90.61 | 93.35 | 92.90 | — | — | — | — | — | — | |
| Operating Margin | -8.07 | -15.74 | -66.12 | — | — | — | — | — | — | |
| Net Margin | -7.74 | -14.63 | -63.39 | — | — | — | — | — | — | |
| Shares Outstanding | 43 | 42 | 38 | — | — | — | — | — | — | |
| Market Capitalization | 2,873 | 3,439 | 2,104 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair | Jun 17 '26 | Sale | 61.55 | 10,000 | 615,489 | 847,991 | Jun 22 |
| Farrow Jeffrey S | See Remarks | Jun 16 '26 | Sale | 60.95 | 14,396 | 877,436 | 56,801 | Jun 17 |
| Farrow Jeffrey S | See Remarks | Jun 15 '26 | Option Exercise | 0.00 | 27,881 | 0 | 71,197 | Jun 17 |
| Goodrich Katherine | Director | Jun 15 '26 | Sale | 62.08 | 2,954 | 183,384 | 2,233 | Jun 17 |
| LINK WILLIAM J PHD | Director | Jun 15 '26 | Sale | 62.12 | 12,500 | 776,495 | 106,786 | Jun 17 |
| CHAUDHURI BHASKAR | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 11,654 | Jun 16 |
| Morrison Scott W | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 7,638 | Jun 16 |
| LINK WILLIAM J PHD | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 119,286 | Jun 16 |
| Goodrich Katherine | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 5,187 | Jun 16 |
| YARNO WENDY L | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 16,654 | Jun 16 |
| Goldberg Andrew D. | Director | Jun 12 '26 | Option Exercise | 0.00 | 2,954 | 0 | 19,654 | Jun 16 |
| PYOTT DAVID E I | Director | Apr 24 '26 | Option Exercise | 0.00 | 1,383 | 0 | 1,383 | Apr 28 |
| Neervannan Seshadri | Chief Operating Officer | Mar 20 '26 | Sale | 66.75 | 2,989 | 199,516 | 82,791 | Mar 24 |
| Azamian Bobak R. | President/CEO and Board Chair | Mar 19 '26 | Sale | 67.00 | 11,964 | 801,588 | 33,421 | Mar 19 |
| Whitfield Dianne C. | Chief Human Resources Officer | Mar 19 '26 | Sale | 67.00 | 4,174 | 279,658 | 35,028 | Mar 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.